73 results about "Catenin Proteins" patented technology

The present invention relates to methods of modulating epithelial stem cell lineage by regulating the expression of Lef1 or a BMP inhibitor and/or the stability of β-catenin or the expression of a Wnt; regulating the expression or activity of GATA-3; or regulating BMPR1A activity either at the level of receptor expression or at the level of pathway activation. Methods of regulating E-cadherin, GATA-3, BMPR1A and HK1-hair keratin and methods of identifying agents which modulate the epithelial stem cell lineage are further provided. Such agents are useful for inhibiting or stimulating inner root sheath development or hair follicle formation.

Interaction between MUC1 and β-catenin can be interrupted using polypeptides or antibodies that specifically bind to the binding site on MUC1. Interruption provides the beneficial effect of inhibiting, reducing, and/or retarding invasiveness and metastasis. Fusion polypeptides and antibodies are provided to achieve a therapeutic effect.

The present invention relates to RSPO-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO proteins and modulate β-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO proteins, such as antibodies that specifically bind RSPO1, RSPO2, and/or RSPO3 and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.

A compound of formula (I) is provided which is able to interact with beta-catenin/TCF-4 binding site, having a structure essentially equivalent to a pharmacophore (IA), as herein described.

Methods and therapeutic compositions for the treatment of cancer are disclosed. Specifically, peptides including beta-catenin binding domains and polynucleotide sequences encoding same, such as cadherins and o-catenins and polynucleotide sequences encoding same, effective in methods and compositions for treating cancers associated with abnormally high levels of beta-catenin, such as colon cancers and melanomas.

The present invention relates to a purified molecules, including antibodies, that bind specifically to murine β-catenin phosphorylated at amino acid position Serine⁵⁵² and to orthologs thereof, such as mammalian orthologs, including human orthologs. Methods of making and using such purified molecules are also provided. Kits containing such purified molecules are further provided.

The present invention relates to a transgenic mouse containing a latent oncogenic β-catenin allele capable of spontaneous activation in vivo. The transgenic mouse is useful for the identification of compounds and immunotherapies for the prevention, treatment and/or cure of various forms of cancer associated with β-catenin activation.

Provided is a peptide, which has an anti-inflammatory activity and an activity for promoting osteogenic differentiation, formed from the amino acid sequence selected from the group comprising the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3. And provided is a peptide, which has a hair growth promoting activity, formed from the amino acid sequence selected from the group comprising the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2. A peptide formed from the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, according to the present invention, consequently shows an anti-inflammatory activity by inhibiting an inflammatory cytokine expression and proliferation of inflammatory cells, and consequently promotes osteogenic differentiation by increasing phosphorylation of PI3K, Smad1, Smad5 and Smad8, which contribute to osteogenesis, and by increasing ALP, OPG and BSP expressions. And a peptide formed from the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, according to the present invention, consequently shows efficacy for preventing hair loss and promoting hair growth by promoting proliferation of hair follicle cells and human umbilical vein endothelial cells, increasing phosphorylation of EPK, increasing expressions of PI3K, β-catenin, IGF-1, KGF and Wnt3a which are proteins that contribute to hair growth, and reducing an expression of DKK-1 which is a hairless gene.

The method for detecting that LRP6 is the target gene of miR-29a by using a dual-luciferase reporter gene, the purpose of the present invention is to confirm that miR-29a can be negatively expressed by targeting the 3'UTR of the LRP6 gene through a dual-luciferase reporter gene system Regulates the expression of LRP6. A method for detecting LRP6 as a target gene of miR-29a using a dual-luciferase reporter gene, the method comprising the following steps: (1) constructing a plasmid vector and performing point mutations: (2) dual fluorescence detection. The present invention The beneficial effects are as follows: provide a new method for verifying that miR-29a can negatively regulate the expression of LRP6 by targeting the 3'UTR of the LRP6 gene, and contribute to miR-29a, LRP6 and Wnt/-catenin signaling pathways Elucidation of the pathogenesis of osteogenesis-related diseases involved; contribute to the development of potential drugs for osteogenesis-related diseases involved in miR‑29a, LRP6 and Wnt/‑catenin signaling pathways and the screening of biomarkers.

The invention relates to a preparation method of chitosan derivative nanoparticles for delivering siRNA, and belongs to the technical field of gene biology. A positively charged chitosan hydrochloridesolution can be mixed with an siRNA solution capable of inhibiting protein expression related to proliferation and migration of colon cancer cells, then a carboxymethyl chitosan solution with negative electricity is added, and self-assembly is performed to form chitosan derivative nanoparticles (siRNA-CDNPs) for delivering siRNA through electrostatic interaction between molecules. The chitosan derivative nanoparticles for delivering the siRNA can effectively protect the siRNA under the condition that the pH value is 1.2, and under the condition that the pH value of a colon cancer cell environment is 5.5, controllable release of the siRNA is realized through response to external stimulation (ultrasound); the siRNA-CDNPs can effectively inhibit the expression of beta-catenin protein in colon cancer cells, and is expected to inhibit the proliferation and migration of cancer cells. The preparation method is easy to operate, green, environment-friendly and low in cost.

The invention provides application of E3 ubiquitin ligase VHL in degradation of beta-catenin protein or inhibition of a Wnt/beta-catenin signal pathway and a conjugate as well as a preparation methodand application of the conjugate. The conjugate comprises a first peptide fragment suitable for binding to beta-catenin protein; a second peptide fragment suitable for binding to E3 ubiquitin ligase VHL; a connecting arm, wherein the first peptide fragment is connected with second peptide fragment through the connecting arm. The E3 ubiquitin ligase VHL can be used for carrying out ubiquitination modification on beta-catenin protein, so that the ubiquitination beta-catenin protein is degraded by protease, a Wnt/beta-catenin signal channel is inhibited, and the effects of inhibiting cancer cellproliferation and tumor-forming ability are achieved; wide scientific research and clinical application prospects are realized.